

*EIT Health aims to build a strong and balanced Innovation portfolio, with solutions of the greatest potential for societal and economic impact in Europe.*

*Our goals for Portfolio Development are aligned: together with expert opinion, we will look at Strategic fit, Risk and return, Solution maturity and Health impact, to build a strong and balanced Innovation portfolio.*



**Step 1:** Impact and Financial sustainability check is performed after Remote Evaluation

**Step 2:** Based on ranking generated from scores (25% remote +75% hearings) and Due Diligence results, Portfolio Development analyzes four dimensions to provide insights about top projects

**Step 3:** Discussion of dimensions and decision at MB level

**Step 4:** Communication of result to partners (Activity Leaders)

### STEP 1

Impact and Financial sustainability check is performed after Remote Evaluation to determine the invitation to Hearings. Projects that went through Hearings will obtain a new score from external reviewer panels.

### STEP 2

Portfolio Development begins with the result of evaluators' rankings (25% remote + 75% hearings). For projects applying with Startup Amplifier instrument, Due Diligence results are also considered in this step, and only projects with those startups which passed Due Diligence will be moved forward to further steps of Portfolio Development and be considered for funding.

The following four dimensions will be analyzed to facilitate discussions during Portfolio Development:

- Strategic fit (Focus Area & project type)
- Risk and return (Innovation risk and potential revenue)
- Solution maturity and market readiness
- Health impact (number and geographic distribution of patients / users impacted by proposed solution)

### STEP 3

Discussion of different dimensions and projects will take place at MB level. During the discussion, all MB members can contribute their opinion, focusing on how to build a strong and balanced portfolio.

### STEP 4

After final decision at MB, funding announcement is communicated to BP2022 applicants for Innovation projects.

*Disclaimer: this development is applicable to Innovation proposals for BP2022. EIT Health foresees the possibility of adjustments corresponding to our strategic agenda in future BPs.*

### What are we looking for in BP2022?

The dimensions to focus in, properties to look for, and goals to achieve.

Dimensions	Properties	Goals
Strategic fit	Number of Innovation projects per Focus Area	We aim for a balanced number of projects in each Focus Area, but project quality should be sustained. There should <b>NOT</b> be actions taken to only secure a “guaranteed spot” for each Focus Area.
	Type of Innovation projects	We aim for a balanced number of projects in each type, but project quality should be sustained. There should <b>NOT</b> be actions taken to only secure a “guaranteed spot” for each project type.
Risk and return	Percentage of projects that are financially promising or value-creating, with lower innovation risk	At least 15% of funded projects in BP2022 should be financially promising / socioeconomic value-creating, with lower innovation risk.
Solution maturity	Market and Adoption readiness	Projects that are able to facilitate adoption (for HVC projects*) or obtain first sales (for non-HVC projects) at / before end of project shall be appreciated.
Health Impact	Patients / users / beneficiaries impacted by the solution	Higher number of patients / users / beneficiaries positively impacted by the solution shall be appreciated.
General	CLC representation	No quotas per CLC shall be observed.
	Disease or technology concentrations	No quotas shall be observed.

\*For HVC projects, please refer to details included in the Annex of 2022 Business Plan Calls.

*Disclaimer: this development is applicable to Innovation proposals for BP2022. EIT Health foresees the possibility of adjustments corresponding to our strategic agenda in future BPs.*